Table 1 Baseline clinical and pathologic features of patients with hepatocellular carcinoma in all four cohorts

From: Clinical significance of APOB inactivation in hepatocellular carcinoma

Variable

Cohort, n (%)

MDACC

Samsung

Fudan

TCGA

Total number of patients

88

240

242

371

Sexa

Ā ā€ƒMale

73 (83)

199 (83)

211 (87)

73 (20)

Ā ā€ƒFemale

15 (17)

41 (17)

31 (13)

15 (4)

ā€ƒNA

Ā Ā Ā 

283 (76)

Age (years)

Ā ā€ƒMedian

58

53

50

61

Ā ā€ƒRange

29ā€“77

17ā€“76

21ā€“77

17ā€“90

AFP

Ā ā€ƒ>300ā€‰ng/ml

23 (26)

78 (33)

110 (45)

Ā 

Ā ā€ƒā‰¤300ā€‰ng/ml

64 (73)

154 (64)

128 (53)

Ā 

Ā ā€ƒNA

1 (1)

8 (3)

4 (2)

371 (100)

HBV

Ā ā€ƒ+

80 (91)

206 (86)

242 (100)

Ā 

Ā ā€ƒā€“

8 (9)

34 (14)

0 (0)

Ā 

ā€ƒNA

Ā Ā Ā 

371 (100)

AJCC stage

Ā ā€ƒI

68 (77)

102 (43)

96 (40)

164 (44)

Ā ā€ƒII

13 (15)

99 (41)

78 (32)

82 (22)

Ā ā€ƒIII

7 (8)

34 (14)

51 (21)

78 (21)

Ā ā€ƒIV

0

5 (2)

0 (0)

5 (1)

Ā ā€ƒNA

Ā Ā 

17 (7)

42 (11)

BCLC stage

Ā ā€ƒ0

4 (5)

1 (1)

20 (8)

Ā 

Ā ā€ƒA

53 (60)

138 (57)

152 (63)

Ā 

Ā ā€ƒB

26 (30)

91 (38)

24 (10)

Ā 

Ā ā€ƒC

5 (6)

10 (4)

29 (12)

Ā 

Ā ā€ƒD

Ā Ā 

0 (0)

371 (100)

Ā ā€ƒNA

Ā Ā 

17 (7)

Ā 

Ā Death

17 (19)

108 (45)

96 (40)

121 (33)

Ā Median follow-up duration

31.5 months

91 months

51.6 months

19.7 months

  1. MDACC The University of Texas MD Anderson Cancer Center, TCGA The Cancer Genome Atlas, NA not applicable, AFP alpha-fetoprotein, HBV hepatitis B virus, AJCC American Joint Committee on Cancer staging system, BCLC Barcelona Clinic Liver Cancer staging system
  2. aPatient sex was not available for patients who underwent liver transplantation
Back to article page